|
Jan 12
|
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
|
|
Dec 26
|
Karuna downgraded, Arm target raised: Wall Street's top analyst calls
|
|
Dec 22
|
Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls
|
|
Dec 22
|
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
|
|
Nov 2
|
AlloVir Inc (ALVR) Reports Q3 2023 Financial Results
|
|
Nov 2
|
AlloVir Reports Third Quarter 2023 Financial Results
|
|
Aug 28
|
AlloVir to Present at Upcoming Investor Conferences
|
|
Jul 4
|
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
|